Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

<< Previous

Bullboard Posts

Next >>

Post by mercedesmanon Jan 31, 2024 9:12am

187 Views

Post# 35854564

Ronco & Kellum strike again

Once one grasps the concept of Precision Medicine and heretofore heterogeneity of patient populations in previous trials/studies - one understands why we are on the cusp of a breakthrough for new more targeted procedures such as hemoabsorption.

Ronco and our very own JK combine forces to discuss...

Which Patient Phenotype Is the Ideal Candidate for Hemoadsorption in Acute and Chronic Kidney Disease

in a new 2024 article.

https://journals.lww.com/imna/fulltext/2024/03000/which_patient_phenotype_is_the_ideal_candidate_for.1.aspx

<< Previous

Bullboard Posts

Next >>

Consumer advocacy law firm investigates Microsoft over X-Box data concerns